Combining T-DXd with FP/pembrolizumab (pembro) 200 mg showed durable clinical benefit in pts with HER2+ central PD-L1 CPS ≥1 esophageal/gastric/GEJA. Adjudicated drug-related interstitial lung disease (ILD)/pneumonitis occu...
[41]Janjigian YY, Kawazoe A, Bai Y, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial[J]...
在ToGA 研究确立抗 HER2 抗体 trastuzumab 联合化疗作为既往未治疗的晚期 HER2 阳性 G/GEJC 患者的标准治疗十年后,将免疫检查点抑制剂(抗 PD-1 抗体 pembrolizumab)加入该方案,为这种疾病提供了新的第一线治疗选择。 已识别出多种 HER2 靶向治疗的潜在耐药机制,例如导致药物结合 HER2 受损的改变或下游或平行于 HE...
2017年5月,PD-1抑制剂帕博利珠单抗(pembrolizumab)被美国FDA批准用于治疗无论肿瘤来源,微卫星不稳定性高(MSI-H)或错配修复缺陷(dMMR)的成人和儿童实体瘤患者,成为全球首个获得FDA批准的泛实体瘤疗法。 2018年11月,TRK抑制剂拉罗替尼(larotrectinib)被美国FDA批准用于治疗具有神经营养受体酪氨酸激酶(Neurotrophic ty...
7.Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer[J]. New England Journal of Medicine, 2018, 378(22): 2078-2092. 8.https://www.fda.gov/patients/learn-about-drug-and-device-approvals/fast-track-breakthrough-therapy...
January 15, 2021 - Pembrolizumab with trastuzumab and the combination of cisplatin and capecitabine appeared effective in treating HER2-positive advanced gastric and gastroesophageal junction cancer, regardless of a patient’s PD-L1 status. Sun Young Rha, MD, PhD Pembrolizumab (Key...
17. Janjigian YY, et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2020 Jun;21(6):821-831. 王晰程
标题:Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: overall survival data from the 1st line non-small cell lung carcinoma (NSCLC) cohort of TACTI-002 (Phase II) 结合抗原呈递细胞激活剂eftilagimod alpha(可溶性LAG-3)和pembrolizumab:来自TACTI-00...
Weiss on How Nanoparticles are Enhancing Radiation Therapy in Lung Cancer SC Pembrolizumab Noninferior to IV in NSCLC: Phase 3 Trial Results Behind the Phase 3 3475A-D77 Trial of SC Pembrolizumab in NSCLC Phase 3 Trial Evaluates SC Pembrolizumab vs IV in NSCLC ...
临床前数据表明,ADC抗癌药物Enhertu能增强抗肿瘤免疫力,与PD-1抗体配伍后,证明比单独使用其中一种方法更有效。Enhertu与靶向PD-1/PD-L1通路的免疫治疗药物具有潜在的叠加效应,可在增强肿瘤免疫原性的同时杀死肿瘤细胞。港安健康国际医疗介绍,根据在2024年ESMO免疫肿瘤学大会上公布的1b期DS8201-A-U106研究(NCT040...